• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Auteur:Piccart-Gebhart, Martine; Bertelsen, K; James, K; Cassidy, J; Mangioni, C; Simonsen, E; Stuart, G; Kaye, Steve; Vergote, Ignace; Blom, R; Grimshaw, R; Atkinson, R J; Swenerton, K D; Trope, C; Nardi, M; Kaern, J; Tumolo, Salvatore; Timmers, P; Roy, J A; Lhoas, F; Lindvall, B; Bacon, M; Birt, A; Andersen, J E; Zee, B; Paul, J; Baron, Benoît; Pecorelli, Sërgio
Informations sur la publication:Journal of the National Cancer Institute, 92, 9, page (699-708)
Statut de publication:Publié, 2000-05
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged, 80 and over
Alopecia -- chemically induced
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Cisplatin -- administration & dosage
Cisplatin -- adverse effects
Combined Modality Therapy
Cross-Over Studies
Cyclophosphamide -- administration & dosage
Cyclophosphamide -- adverse effects
Disease Progression
Follow-Up Studies
Middle Aged
Nausea -- chemically induced
Neoplasm Staging
Neutropenia -- chemically induced
Ovarian Neoplasms -- drug therapy
Ovarian Neoplasms -- mortality
Ovarian Neoplasms -- surgery
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Survival Analysis
Thrombocytopenia -- chemically induced
Time Factors
Treatment Outcome
Vomiting -- chemically induced
Note générale:Clinical Trial
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't